Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.6 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.3, delivering a surprise of +14.29%.Over the last four quarters, the company ...

Company Overview - TG Therapeutics (TGTX) is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings projected at $0.35 per share, reflecting a +133.3% change, and revenues expected to be $189.4 million, up 75.1% from the previous year [3]. Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 12.93% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate for TG Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.43%, which complicates the prediction of an earnings beat [12]. Earnings Surprise History - In the last reported quarter, TG Therapeutics had a significant earnings surprise, posting earnings of $2.43 per share against an expected $0.24, resulting in a surprise of +912.50% [13]. - Over the last four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - In comparison, Mirum Pharmaceuticals, Inc. (MIRM) is expected to post earnings of $0.02 per share for the same quarter, indicating a year-over-year change of +104.1%, with revenues projected at $141.27 million, up 42.1% [18]. - Mirum Pharmaceuticals has seen a significant upward revision of its EPS estimate by 50.9% over the last 30 days, resulting in an Earnings ESP of +675.00%, suggesting a strong likelihood of beating the consensus EPS estimate [19][20].

Core Insights - ImmunityBio (IBRX) shares surged 41.9% to close at $8.54, reversing a previous 7.1% loss over the past four weeks, supported by high trading volume [1][2] Company Developments - The significant share price increase was driven by the European Commission granting conditional approval for ImmunityBio's Anktiva plus BCG therapy for treating BCG-unresponsive non-muscle invasive bladder cancer, expanding its market presence to 33 countries [2] - This approval marks the first immunotherapy authorized in Europe for this specific indication, enhancing the company's growth prospects [2] Financial Expectations - ImmunityBio is projected to report a quarterly loss of $0.08 per share, reflecting a year-over-year increase of 46.7%, with expected revenues of $37.1 million, up 391.4% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 6.3% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - ImmunityBio operates within the Zacks Medical - Biomedical and Genetics industry, where Mirum Pharmaceuticals, another company in the sector, has seen a 2.2% increase in its stock price, closing at $105.1, with an 11.9% return over the past month [4] - Mirum Pharmaceuticals has a consensus EPS estimate that has changed by +50.9% over the past month, indicating a significant year-over-year change of +104.1% [5]

Core Insights - Three stocks in the health care sector are signaling potential warnings for momentum-focused investors as of February 2, 2026 [1] Group 1: Momentum Indicators - The Relative Strength Index (RSI) is a key momentum indicator that compares a stock's performance on days with price increases to days with price decreases, helping traders gauge short-term performance [2] - A stock is generally considered overbought when its RSI exceeds 70, indicating potential caution for investors [2] Group 2: Specific Stocks - Brookdale Senior Living Inc (NYSE:BKD) and Mirum Pharmaceuticals Inc (NASDAQ:MIRM) are highlighted as major overbought stocks in the health care sector [3] - Amicus Therapeutics has seen a significant stock price increase of approximately 139% over the past six months, with a recent RSI value of 80.4, indicating it is overbought [3] - The stock of Amicus Therapeutics closed at $14.29, slightly up by 0.1% on the last trading day, with a 52-week high of $14.38 [3]

Core Insights - Three stocks in the health care sector are signaling potential warnings for momentum-focused investors as of February 2, 2026 [1] Group 1: Momentum Indicators - The Relative Strength Index (RSI) is a key momentum indicator that compares a stock's performance on days with price increases to days with price decreases, helping traders gauge short-term performance [2] - A stock is generally considered overbought when its RSI exceeds 70, indicating potential caution for investors [2] Group 2: Specific Stocks - Brookdale Senior Living Inc (NYSE:BKD) and Mirum Pharmaceuticals Inc (NASDAQ:MIRM) are highlighted as major overbought stocks in the health care sector [3] - Amicus Therapeutics has seen a significant stock increase of approximately 139% over the past six months, with a 52-week high of $14.38 and an RSI value of 80.4, indicating it is overbought [3] - On the last trading day, Amicus Therapeutics' shares closed at $14.29, reflecting a slight gain of 0.1% [3]

Core Viewpoint - Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is highlighted as one of the best stocks to buy, with a recent price target increase from H.C. Wainwright indicating strong future potential for the company [1][2]. Group 1: Price Target Adjustments - H.C. Wainwright raised its price target on Mirum Pharmaceuticals from $102 to $130, maintaining a Buy rating, marking the second increase in two weeks [1][2]. - The price target revisions are based on bullish guidance for 2026, particularly regarding the clinical evaluation of volixibat in chronic immune-mediated cholestatic liver diseases [2]. Group 2: Clinical Developments - Analysts believe that volixibat could launch as early as the first half of 2027, with the VISTAS study in primary sclerosing cholangitis expected to provide topline data in Q2 2026 [2]. - Enrollment for the VISTAS study is anticipated to be completed in the second half of 2026, indicating a critical timeline for the company's product development [2]. Group 3: Stock Performance and Analyst Ratings - Over the past six months, MIRM shares have increased by over 91%, with all 11 analysts covering the stock rating it as a Buy [3]. - The median price target among analysts is set at $103, suggesting a slight upside of just under 4%, while H.C. Wainwright's target of $130 implies an upside potential of almost 31% [3]. Group 4: Company Overview - Mirum Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing therapies for rare and orphan diseases [3].

Core Viewpoint - Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is highlighted as a promising mid-cap growth stock, with multiple analysts raising their price targets following strong preliminary earnings results and positive guidance for 2026 [1][2][3]. Analyst Ratings and Price Targets - Baird analyst Brian Skorney increased the price target for Mirum Pharmaceuticals to $95 from $81, maintaining an Outperform rating due to a beat-and-raise on earnings and guidance [1]. - H.C. Wainwright also raised its price target for Mirum Pharmaceuticals to $102 from $81, while keeping a Buy rating, citing impressive preliminary financial results and bullish guidance for 2026 [2]. - Citizens raised its price target for Mirum Pharmaceuticals to $140 from $95, maintaining an Outperform rating, and noted the company's expected leadership position in 2026, supported by pivotal readouts in its clinical pipeline [3]. Company Overview - Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for rare and orphan diseases [4].

Core Insights - CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) attract investors in the rare-disease biotech sector due to smaller patient populations that can yield significant revenue through premium pricing and regulatory incentives [1] - Both companies benefit from clearer clinical endpoints and faster regulatory pathways, allowing quicker market entry compared to traditional drugs [1] CorMedix (CRMD) Overview - CorMedix's lead product, DefenCath, received FDA approval in late 2023 as the first antimicrobial catheter lock solution in the U.S., aimed at reducing catheter-related bloodstream infections in kidney failure patients [2] - DefenCath generated $167.6 million in net sales in the first nine months of 2025, indicating strong market adoption [7] - The company plans to expand DefenCath's label into total parenteral nutrition and has diversified its revenue through a $300 million acquisition of Melinta Therapeutics, adding seven approved therapies to its portfolio [7] - Despite initial success, CorMedix's future outlook is cautious, with 2026 revenue guidance of $300-$320 million and projected 2027 revenues of $100-$140 million, reflecting pricing pressures and limited growth [8][11] Mirum Pharmaceuticals (MIRM) Overview - Mirum's lead product, Livmarli, is approved for treating cholestatic pruritus in patients with Alagille syndrome and has seen a 70% year-over-year increase in net sales, reaching $161.4 million in the first nine months of 2025 [3][12] - The company has expanded its portfolio with a new tablet formulation of Livmarli and additional bile acid products from the acquisition of Travere Therapeutics, generating $118.8 million in the first nine months of 2025 [16] - MIRM's revenue guidance for 2026 is approximately $630-$650 million, supported by a broader product base and ongoing clinical studies for new therapies [16][28] Comparative Analysis - Both companies exhibit a similar risk-reward profile, but MIRM presents a clearer growth narrative with multiple revenue drivers, while CRMD's outlook is clouded by conservative guidance and reliance on a single product [4][9] - MIRM's shares have increased by 75.3% over the past six months, contrasting with CRMD's 38% decline, indicating market preference for MIRM's growth potential [23] - Valuation metrics show MIRM trading at a price/book ratio of 16.02, significantly higher than CRMD's 1.43, reflecting investor confidence in MIRM's growth prospects [24] Investment Recommendation - Mirum Pharmaceuticals is viewed as the better investment opportunity due to its strong sales growth, diversified revenue streams, and multiple growth levers, while CorMedix faces more uncertainty and competitive pressures [25][29]

Core Insights - Saira Ramasastry, a director at Mirum Pharmaceuticals, executed the exercise of 5,000 stock options and sold the resulting shares for a total transaction value of $400,000 on December 22 [2][7]. Transaction Summary - The transaction involved the direct sale of 5,000 shares, with a total value of $400,000, based on a weighted average purchase price of $80.00 per share [3]. - Post-transaction, Ramasastry holds no direct common shares, as the entire transaction accounted for 100% of her direct holdings [8]. Company Overview - Mirum Pharmaceuticals reported a revenue of $471.79 million and a net income of -$41.42 million for the trailing twelve months (TTM) [5]. - The company's stock price increased by 90.71% over the past year, calculated using December 22 as the reference date [5]. Company Snapshot - Mirum specializes in developing therapies for rare and orphan liver diseases, with its lead product being LIVMARLI and additional candidates like Volixibat in its pipeline [6]. Operational Performance - Preliminary results for 2025 indicate net product sales of approximately $520 million, exceeding guidance, with forecasts of $630 million to $650 million in global net product sales for 2026 [11]. - The company ended 2025 with an estimated $392 million in cash and investments and achieved positive operating cash flow, allowing for pipeline expansion and the proposed acquisition of Bluejay Therapeutics [11].

Core Insights - Enthorin Therapeutics, LLC is focused on circuit-modulating treatments for neurological and neurodevelopmental disorders [1] - The company announced that its licensing partner, Mirum Pharmaceuticals, initiated the BLOOM Phase 2 clinical study for MRM-3379 in Fragile X syndrome [1] - MRM-3379 is characterized as an orally available, highly brain-penetrant, selective phosphodiesterase inhibitor [1] Company Overview - Enthorin Therapeutics specializes in biotechnology with a focus on neurological and neurodevelopmental disorders [1] - Mirum Pharmaceuticals, Inc. is the licensing partner for MRM-3379 and is publicly traded on NASDAQ under the ticker MIRM [1] Clinical Development - The BLOOM Phase 2 clinical study aims to evaluate the efficacy of MRM-3379 in treating Fragile X syndrome [1] - MRM-3379 is noted for its ability to penetrate the brain effectively, which is crucial for its therapeutic application [1]